Jeng-Sen Tseng
Overview
Explore the profile of Jeng-Sen Tseng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
720
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kuo C, Su P, Wei Y, Ko J, Tseng J, Su J, et al.
Am J Cancer Res
. 2023 Aug;
13(7):3100-3112.
PMID: 37559987
Real-world data regarding the T790M mutation rate after acquiring resistance to first-line combination therapy with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and bevacizumab in patients with advanced non-small-cell lung...
12.
Wang C, Hsu K, Chang Y, Ho C, Chiang C, Chen K, et al.
J Thorac Oncol
. 2023 Jul;
18(11):1492-1503.
PMID: 37414358
Introduction: The role of a family history of lung cancer (LCFH) in screening using low-dose computed tomography (LDCT) has not been prospectively investigated with long-term follow-up. Methods: A multicenter prospective...
13.
Chen K, Huang Y, Hsu K, Tseng J, Chang G, Yang T
Onco Targets Ther
. 2023 May;
16:317-326.
PMID: 37220494
Purpose: Although serum neutrophil-to-lymphocyte ratio (NLR) is correlated with the outcome of various cancer types, its role in treatment-naïve, advanced, ()-mutant non-small cell lung cancer (NSCLC) patients treated with osimertinib...
14.
Lee P, Chiang C, Tseng J, Zheng Z, Chen K, Chu C, et al.
Front Oncol
. 2023 Mar;
13:1096683.
PMID: 36925928
Introduction: For patients with T2aN0 stage IB lung adenocarcinoma, benefits of adjuvant chemotherapy remain controversial. Here, we aimed to evaluate such benefits. Methods: This retrospective cohort study was conducted on...
15.
Lee P, Huang Y, Hsu Y, Chen K, Hsu K, Lin H, et al.
J Clin Med
. 2023 Jan;
12(1).
PMID: 36615034
(1) Background: We aimed to evaluate the risk of hepatitis B virus (HBV) reactivation in lung cancer patients treated with tyrosine kinase inhibitor (TKI), particularly in those with resolved HBV...
16.
Huang Y, Hsu K, Tseng J, Yang T, Chen K, Su K, et al.
Target Oncol
. 2022 Nov;
18(1):179-180.
PMID: 36334173
No abstract available.
17.
Huang Y, Chiu S, Tseng J, Chen J, Wei T, Chu C, et al.
J Cell Physiol
. 2022 Oct;
237(12):4517-4530.
PMID: 36250981
Golgi apparatus (GA) and centrosome reposition toward cell leading end during directional cell migration in a coupling way, thereby determining cell polarity by transporting essential factors to the proximal plasma...
18.
Wu J, Huang J, Hsu K, Huang Y, Chen K, Tseng J, et al.
Anticancer Drugs
. 2022 Oct;
33(10):e842-e849.
PMID: 36206101
Objective: Immunotherapy plus etoposide and platinum (EP)-based chemotherapy is the standard of care for patients with extensive stage-small cell lung carcinoma (ES-SCLC). In the era of immunotherapy, the role of...
19.
Chu C, Huang Y, Lee P, Hsu K, Chen K, Su K, et al.
PLoS One
. 2022 Aug;
17(8):e0273207.
PMID: 35980949
We aimed to evaluate whether different driver mutations have varying impacts on the programmed cell death-ligand 1 (PD-L1) expression of non-small cell lung cancer (NSCLC), and whether the prognostic roles...
20.
Lee P, Huang Y, Lin H, Hsu K, Chen K, Tseng J, et al.
Medicina (Kaunas)
. 2022 Jul;
58(7).
PMID: 35888627
: Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is one of the standard-of-care therapies in patients with -mutant lung adenocarcinoma; however, acquired resistance inevitably developed. Despite the proposition...